A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

Conclusions ASLAN-002 is well tolerated at 300  mg BID and is the recommended dose for future phase II studies (RP2D). Clinical Trials Registry Number:NCT01721148.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research